Androgen and Bone Woraluk Somboonporn Faculty of Medicine Khon Kaen University.

Slides:



Advertisements
Similar presentations
General Conclusions: Special Considerations for Women With IBD Women have more severe symptoms, more disease concerns than men Women have more severe symptoms,
Advertisements

Preventing Bone Loss in Early Postmenopausal Women A CME Slide Library From the Council on Hormone Education.
Patient Management Issues in Menopause
Osteoporosis Dr. Aisha Sheikh FCPS (Pak), Fellowship Diabetes/Endocrinology (AKUH), PG Dip Diab (UK) Consultant Endocrinologist.
Physical Activity and Bone Health during Childhood and Adolescence: Critical Periods for the Prevention of Osteoporosis Suggested Links (click below)
Elonva in poor responders
Effect of transdermal vs.oral estrogen therapy on achieving near final adult height and near peak bone mass in growth hormone treated adolescents with.
Robertson JFR et al. J Clin Oncol 2009;27(27):
King Abdul Aziz University Faculty Of Pharmacy
Treatment. Bisphosphonates Promotes bone formation and decreases bone resorption Mechanism of Action First line treatment for osteoporosis in both men.
Osteoporosis. Introduction Osteoporosis is “a disease of the bones that happens when you lose too much bone, make too little bone, or both.” - National.
Testosterone  Testosterone is a steroid hormone from the androgen group.  It is synthesized in the testes of males, the ovaries of females, and the adrenal.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
ECTS symposium 5 Anabolic treatment of osteoporosis.
METHODS This evidenced-based literature review compares the use of GnRHa therapy and laparoscopic ablation with respect to symptom relief, recurrence of.
Bone Conditions Unit 3, Lesson 2.
A Comparison of the Effectiveness of Estrogen-Progesterone and Estrogen-Testosterone Combination Therapies in the Prevention of Osteoporosis in Postmenopausal.
The level of evidence utilized to answer general practitioners’ questions Karen Davies.
END ‘Hot topic’ DHEAS miraculous potion or snake oil? © Dr S Nussey &  IOS.
Bone Turnover Suppression Based on an ASBMR/ECTS Clincal Debate “Too Much Suppression of Turnover Is Bad for Bone” Co-Chairs: Socrates Papapoulos, Douglas.
Glucocorticoid-Induced Osteoporosis (GIO) Nguyen Thy Khue, MD, PhD Department of Endocrinology, HoChiMinh City University of Medicine and Pharmacy.
TERIPARATIDE (r-hPTH 1-34) Endocrinologic and Metabolic Drugs Advisory Committee Holiday Inn, Bethesda MD July 27, 2001 Bruce S. Schneider, MD CDER FDA.
A Look at Osteoporosis Screening Guidelines Cynthia Phelan PGY
The role of estrogen in osteoporosis
Period 1 Physiology, Ms. Middleton Miguel Silva, Ethan Rivas At The Clinic Scenario: Endocrine System #5.
Bone Remodeling Bone remodeling = combination of bone deposition and bone resorption. Deposition = taking minerals (Ca2+, Mg2+, Mn2+, phosphate) from the.
WEEK 3 EBCR – 8A Sri Puspita Amalia NP Lingga S Rienna Diansari Harsya DG Tutor : dr.Dewi Friska.
Chapter 6: Osseous Tissue and Bone Structure 1. 2.
Food and Drug Administration Regulatory Implications of The WHI Study Eric Colman, MD Center for Drug Evaluation and Research Division of Metabolic and.
 Skeletal System: Day Three Bone Formation, Growth, and Remodeling, Bone Diseases and Disorders.
Final Analysis of Overall Survival for the Phase III CONFIRM Trial: Fulvestrant 500 mg versus 250 mg Di Leo A et al. Proc SABCS 2012;Abstract S1-4.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 65 Androgens.
A Comparison of Fulvestrant 500 mg with Anastrozole as First-line Treatment for Advanced Breast Cancer: Follow-up Analysis from the FIRST Study Robertson.
Hormone replacement therapy: practical considerations Marco Gambacciani and Nick Panay.
FDA’s Osteoporosis Guidance Center for Drug Evaluation and Research Division of Metabolic and Endocrine Drugs Eric Colman, MD September 25, 2002.
Investigating infertile couple
Copyright © 2010 Pearson Education, Inc. 6-3 Ossification and appositional growth are mechanisms of bone formation and enlargement.
ENDOCRINE SYSTEM AND THE HUMAN EYE Rayvin Ewers Savana Canary Emily Haimes.
Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH Professor, Dept. of Medicine Oregon Health & Science University Portland,
Welcome To Our Presentation
“ The Effects of Oral Contraceptives on Female Athletes’ Bone Mineral Density” By: Megan Grover and Dr. B. Hamilton Abstract: The initial aim of this research.
Sexual Arousal and Response. Hormones involved in sexual arousal Steroid hormones : –Androgens (including testosterone) Produced by testes, adrenal glands,
Ch. 6 … ** Need x-rays of fractures **. 6.4 … E. Bone Remodeling - When: % annually in an adult -Function: 1) 2) 3) - Importance of Calcium  Nerve.
AROMATASE INHIBITORS.
Antidepressant-Induced Sexual Dysfunction
Copyright © 2015 by the American Osteopathic Association.
Skeletal System: Day Three
Male hypogonadism.
Chapter 65 Androgens 1.
First & second line treatments for ED
Case for androgens Giorgio Arnaldi Clinica di Endocrinologia
Bone Growth Notes.
Bone Formation.
Bone Biology and Osteoporosis: Back to the Basics
Case Study. Managing Medication and Adherence in SIHD: Partnering With the Patient to Improve Care.
1/3/2019 OSTEOPOROSIS.
Bone Biology and Osteoporosis: Back to the Basics
Reproductive pharmacology
BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.
Bone Biology and Osteoporosis: Back to the Basics
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:
Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis 
Original Article Testosterone for Low Libido in Postmenopausal Women Not Taking Estrogen Susan R. Davis, M.D., Ph.D., Michele Moreau, M.D., Robin Kroll,
Cancer Treatment-Induced Bone Loss (CTIBL) in Prostate Cancer: Pathophysiology, Preclinical Findings, and Treatment with Zoledronic Acid  Theresa A. Guise,
(Relates to Chapter 64, “Focous on osteoperosis ,” in the textbook)
Estrogen and Bone: Osteoclasts Take Center Stage
Reporting the Results of DXA Scan
Change in cortical bone thickness among 64 women with osteopenia randomised to 14-month treatment with no mineral therapy (red bar), calcium gluconate.
Glucocorticoid-induced osteoporosis: An update on effects and management  Bjoern Buehring, MD, Ravi Viswanathan, MD, Neil Binkley, MD, William Busse, MD 
Fertility Preservation in Breast Cancer
Presentation transcript:

Androgen and Bone Woraluk Somboonporn Faculty of Medicine Khon Kaen University

Androgen and Bone General aspect of androgen action Androgen therapy in men Androgen therapy in women

General aspect of androgen action Loss of estrogens or androgens increases the rate of bone remodelling resorption > formation Vanderschueren et al. Endocrine Reviews. 2004

General aspect of androgen action Maintain cancellous bone mass via ER and AR Increase cortical bone size via stimulation of both longitudinal and radial growth Vanderschueren et al. Endocrine Reviews. 2004

General aspect of androgen action Maintain cancellous bone mass via ER and AR increase cortical bone size Biphasic effect on endochondral formation At the start of puberty: stimulate endochondral bone formation At the end of puberty: induce epiphyseal closure (clearly mediated via aromatization and interaction with ERα Vanderschueren et al. Endocrine Reviews. 2004

Androgen therapy in women

At 12 months Somboonporn W et al 2005 Cochrane Library (In press )

At 24 months Somboonporn W et al 2005 Cochrane Library (In press )

Androgen therapy in women Three studies showed inconsistent results. Two studies showed no significant effect between treatment groups (1,2) Another study demonstrated a significantly greater improvement (3) (1,2) Garnett 1992; Watts 1995 (3) Barrett-Conner 1999

Androgen therapy in women Bone markers One open randomized study reported a significant increase in all bone formation markers. (1) (1) Raisz 1996

Clinical application A systematic review indicates a benefit of adding testosterone to HT to improve sexual outcome. Somboonporn W et al 2005 Cochrane Library (In press )

Clinical application BUT No information as to which patients are most likely to benefit from testosterone therapy. The safety data is limited to surrogate endpoints in the small number of subjects exposed to a very short term use.

Androgen therapy in women We cannot make recommendation for routine use of testosterone in postmenopausal women. Somboonporn W. Seminars in reproductive medicine. In press

Androgen therapy in men

Vanderschueren et al. Endocrine Reviews. 2004

Androgen therapy in men T replacement in indications other than overt hypogonadism Young men with delayed puberty PADAM Eugonadal men Glucocorticoid-treated men suffering from osteoporosis Vanderschueren et al. Endocrine Reviews. 2004

Androgen therapy in men T replacement in indications other than overt hypogonadism Young men with delayed puberty PADAM Eugonadal men Glucocorticoid-treated men suffering from osteoporosis Current scientific evidence does not allow recommending T replacement Vanderschueren et al. Endocrine Reviews. 2004